Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.880
+0.030 (1.62%)
At close: Nov 14, 2025, 4:00 PM EST
1.850
-0.030 (-1.60%)
After-hours: Nov 14, 2025, 6:23 PM EST
Opus Genetics Revenue
Opus Genetics had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -20.38%. This brings the company's revenue in the last twelve months to $14.63M, up 74.60% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$14.63M
Revenue Growth
+74.60%
P/S Ratio
6.38
Revenue / Employee
$812,944
Employees
18
Market Cap
118.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRD News
- 2 days ago - Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease - GlobeNewsWire
- 3 days ago - Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Opus Genetics Announces $23 Million Registered Direct Offering - GlobeNewsWire
- 9 days ago - Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease - GlobeNewsWire
- 11 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 6 weeks ago - Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewsWire
- 6 weeks ago - Opus Genetics, Inc. - Special Call - Seeking Alpha